MARKET

VRCA

VRCA

Verrica Pharmaceuticals
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.72
+0.24
+3.70%
Pre Market: 6.72 0 0.00% 08:21 08/06 EDT
OPEN
6.61
PREV CLOSE
6.48
HIGH
6.88
LOW
6.37
VOLUME
308
TURNOVER
--
52 WEEK HIGH
18.67
52 WEEK LOW
6.13
MARKET CAP
173.47M
P/E (TTM)
-5.4839
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average VRCA stock price target is 17.50 with a high estimate of 25.00 and a low estimate of 10.00.

EPS

VRCA News

More
Verrica Pharma grants option for VP-102 commercialisation in Japan
Verrica Pharmaceuticals (NASDAQ:VRCA) has entered into an option agreement with Torii Pharmaceuticals, granting an option to acquire exclusive license righ
seekingalpha · 19h ago
Verrica Pharmaceuticals EPS beats by $0.08
Verrica Pharmaceuticals (NASDAQ:VRCA): Q2 GAAP EPS of -$0.38 beats by $0.08. Cash, cash equivalents, and marketable securities of $79.6M. Press Release
seekingalpha · 20h ago
Verrica Pharmaceuticals Q2 EPS $(0.38) Down From $(0.28) YoY
Verrica Pharmaceuticals (NASDAQ:VRCA) reported quarterly losses of $(0.38) per share. This is a 35.71 percent decrease over losses of $(0.28) per share from the same period last year.
Benzinga · 1d ago
Verrica Pharmaceuticals Reports Second Quarter 2020 Financial Results
\- Company intends to request a Type A meeting with FDA during the third quarter of 2020 to discuss next steps for resubmission of an NDA for VP-102 following Complete Response Letter - \- Key leadership additions strengthen depth of expertise in Clinical, Ch
GlobeNewswire · 1d ago
Verrica Pharmaceuticals Announces Option Agreement with Torii Pharmaceutical to Develop & Commercialize VP-102 in Japan
WEST CHESTER, Pa., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for viral skin diseases requiring medical interventions, today announced it has entered into
GlobeNewswire · 1d ago
Investor Alert: Kaplan Fox Investigates Verrica Pharmaceuticals Inc. For Potential Securities Fraud
Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (NASDAQ: VRCA). A complaint has been filed on behalf of investors that purchased Verrica securities betw
PR Newswire · 1d ago
LEAD PLAINTIFF DEADLINE: Johnson Fistel, LLP Encourages Investors to Contact the Firm
Johnson Fistel, LLP, announces that class action lawsuits have been commenced on behalf of shareholders of the publicly-traded companies listed below. The Private Securities Litigation Reform Act of 1995 permits any investor who purchased common stock during t
PR Newswire · 3d ago
The Daily Biotech Pulse: Bristol-Myers, Bluebird Bio Resubmit Multiple Myeloma Drug BLA, FSD To Close Medicinal Cannabis Business, Hologic's Blowout Quarter
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 29)
Benzinga · 07/30 12:09

Industry

Pharmaceuticals
+0.34%
Pharmaceuticals & Medical Research
+0.35%

Hot Stocks

Symbol
Price
%Change

About VRCA

Verrica Pharmaceuticals Inc. is a United States-based clinical-stage medical dermatology company. The Company is focused on identifying, developing and commercializing pharmaceutical products for the treatment of skin diseases with unmet needs. Its lead product candidate, VP-102, is a drug-device combination of topical solution of cantharidin. The Company also intends to develop second cantharidin-based product candidate, VP-103, for the treatment of plantar warts. The Company has completed one Phase II clinical trial of topical solution of cantharidin administered with the wooden stick part of a cotton-tipped swab. It also conducting another Phase II clinical trial of topical solution of cantharidin administered through applicator, which collectively refer to as VP-102, for the treatment of molluscum.
More

Webull offers kinds of Verrica Pharmaceuticals Inc stock information, including NASDAQ:VRCA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VRCA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VRCA stock methods without spending real money on the virtual paper trading platform.